M
Matthias Kroiss
Researcher at University of Würzburg
Publications - 179
Citations - 6738
Matthias Kroiss is an academic researcher from University of Würzburg. The author has contributed to research in topics: Adrenocortical carcinoma & Medicine. The author has an hindex of 34, co-authored 135 publications receiving 4793 citations. Previous affiliations of Matthias Kroiss include Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Martin Fassnacht,Massimo Terzolo,Bruno Allolio,Eric Baudin,Harm R. Haak,Alfredo Berruti,Staffan Welin,Carmen Schade-Brittinger,André Lacroix,Barbara Jarzab,Halfdan Sorbye,David J. Torpy,Vinzenz Stepan,David E. Schteingart,Wiebke Arlt,Matthias Kroiss,Sophie Leboulleux,Paola Sperone,Anders Sundin,I G C Hermsen,Stefanie Hahner,Holger S. Willenberg,Antoine Tabarin,Marcus Quinkler,Christelle De La Fouchardiere,Martin Schlumberger,Franco Mantero,Dirk Weismann,Felix Beuschlein,Hans Gelderblom,Hanneke Wilmink,Monica Sender,Maureen Edgerly,Werner Kenn,Tito Fojo,Hans-Helge Müller,Britt Skogseid +36 more
TL;DR: Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus Mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival.
Journal ArticleDOI
Integrated genomic characterization of adrenocortical carcinoma
Guillaume Assié,Eric Letouzé,Martin Fassnacht,Anne Jouinot,W. Luscap,Olivia Barreau,H. Omeiri,S. Rodriguez,Karine Perlemoine,Fernande René-Corail,Nabila Elarouci,Silviu Sbiera,Matthias Kroiss,Bruno Allolio,Jens Waldmann,Marcus Quinkler,Massimo Mannelli,Franco Mantero,Thomas G. Papathomas,Ronald R. de Krijger,Antoine Tabarin,Véronique Kerlan,Eric Baudin,Frédérique Tissier,Bertrand Dousset,Lionel Groussin,Laurence Amar,Eric Clauser,Xavier Bertagna,Bruno Ragazzon,Felix Beuschlein,Rossella Libé,Aurélien de Reyniès,Jérôme Bertherat +33 more
TL;DR: Aggressive and indolent ACCs correspond to two distinct molecular entities driven by different oncogenic alterations, which are validated in an independent cohort of 77 ACCs.
Journal ArticleDOI
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J. Wirth,Eric J. Sherman,Bruce G. Robinson,Benjamin Solomon,Hyunseok Kang,Jochen H. Lorch,Francis P. Worden,Marcia S. Brose,Jyoti D. Patel,Sophie Leboulleux,Yann Godbert,Fabrice Barlesi,John C. Morris,Taofeek K. Owonikoko,Daniel Shao-Weng Tan,Oliver Gautschi,Jared Weiss,Christelle De La Fouchardiere,Mark E. Burkard,Janessa Laskin,Matthew H. Taylor,Matthias Kroiss,Jacques Medioni,Jonathan W. Goldman,Todd M. Bauer,Benjamin Levy,Viola W. Zhu,Nehal Lakhani,Victor Moreno,Kevin Ebata,Michele Nguyen,Dana Heirich,Edward Y. Zhu,Xin Huang,L. Yang,Jennifer Kherani,S. Michael Rothenberg,Alexander Drilon,Vivek Subbiah,Manisha H. Shah,Maria E. Cabanillas +40 more
TL;DR: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment.
Journal ArticleDOI
Adrenocortical carcinoma: a clinician's update
TL;DR: In patients with suspected adrenocortical carcinoma, a thorough endocrine and imaging work-up is recommended to guide the surgical approach aimed at complete resection of the tumor, and mitotane is the cornerstone of initial treatment, and cytotoxic drugs should be added in case of progression.
Journal ArticleDOI
Update in Adrenocortical Carcinoma
TL;DR: In advanced ACC, mitotane plus etoposide, doxorubicin, and cisplatin is now the established first-line cytotoxic therapy, however, most patients will experience progress and require salvage therapies, and new treatment concepts are urgently needed.